Summit Therapeutics Inc.
SMMT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001599298
No open-market purchases or sales by Summit Therapeutics Inc. insiders were filed in the last 90 days; 242 institutions reported holding it in 13F filings for Q2 2026, worth $1.98B in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Summit Therapeutics Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 38 | 54 | +16 |
| Shares | 9.28M | 11.0M | +1.76M (+18.9%) |
| Value | $54.5M | $82.4M | +$27.9M (+51.1%) |
New holders (24)
Institutions that held Summit Therapeutics Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (8)
Institutions that held Summit Therapeutics Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Millennium Management LLC | 345,723 | $2.03M |
| Susquehanna International Group, LLP | 133,808 | $785.0K |
| ExodusPoint Capital Management, LP | 93,533 | $549.0K |
| HRT Financial LP | 29,906 | $175.0K |
| Inscription Capital, LLC | 17,000 | $100.0K |
| LMR Partners LLP | 14,357 | $84.0K |
| Bender Robert & Associates | 14,059 | $83.0K |
| Close Asset Management Ltd | 800 | $5.00K |